New Beginnings Baptist Church For All People, located at 126 Old Wise School Ext., Wise (Overseer Kevin C. Blalock, senior pastor) will continue its Bible Study “Nugget” series on Tuesday, ...
The World Evangelical Alliance (WEA) concluded its morning program on the fourth and final day of the 2025 General Assembly ...
At the University of Arkansas, a large Division I institution with roughly 34,000 students, it can be easy for students to ...
On the heels of “The Chosen” Season 1’s release, fans of the series expressed a hunger for more faith-based content. Amanda Jenkins, who is the wife of the biblical drama’s creator, Dallas Jenkins, ...
The study, titled “Bible Across America,” is set to begin Nov. 5 and aims to gather Catholics “around God’s word to prayerfully study Scripture.” ...
TROY, Mich.: 8 Oct. 2025 — What would you do with an extra seven minutes and 57 seconds tacked onto your next vacation or business trip? According to the J.D. Power 2025 North America Rental Car ...
Generative AI is moving from drafting emails to shaping labor markets. On platforms like Fiverr, Freelancer.com, and Upwork, millions of workers rely on hourly rates to compete for jobs. As AI ...
The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or ...
Calvary Chapel Chino Hills Pastor Jack Hibbs of California told "Fox and Friends First" this week that Charlie Kirk, the founder of Turning Point USA, helped many young Americans find their purpose — ...
The study by X-energy Canada has confirmed the feasibility and benefits of repurposing an existing thermal generation site in Alberta with X-energy's small modular reactors, and establishes a ...
Advances in AI technology have ushered in a new era of digital romance, where people are forming intimate emotional connections with chatbots. For many, these AI companions are a crucial lifeline, ...
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, ...